Τόμος 27 (2009) – Τεύχος 1 – Άρθρο 18 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 27 (2009) – Issue 1– Article 18 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ι. Μελακόπουλος, Χ. Τεσσερομμάτη

Eργαστήριο Φαρμακολογίας Ιατρικής Σχολής, Πανεπιστημίου Αθηνών Μικράς Ασίας 75, Αθήνα 11527, Ελλάς

I. Melakopoulos, C. Tesseromatis

Laboratory of Experimental Pharmacology, Medical School, University of Athens, M. Asias 75, Athens 11527, Hellas

2. Russell G., Xia Z., Dunford J., Opperman U., et al.: Bisphosphonates an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. : 209-257 (2007)

3. Rogers M., Gordon S., Benford H et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer Supp. 88(12 Suppl): 2961-2978 (2000)

4. Wang J., Goodger N.M., Pogrel M.A.: Osteonecrosis of the jaws associated with cancer chemotherapy. J. Oral Maxillofac. Surg. 61: 1104-1107 (2003)

5. Marx R.: Pamidronate and zoledronate induced avascular necrosis of the jaws: a growing epidemic (Letter to the editor). J. Oral Maxillofac. Surg. 61: 1115-1117 (2003)

6. Migliorati C.: Bisphosphonates and oral cavity avascular bone necrosis. J. Clin. Oncol. 21: 4253-4254 (2003)

7. Μελακόπουλος Ι., Πατρικίου Α.: Οστεονέκρωση της κάτω γνάθου από χρήση διφωσφονικών. Περιγραφή περίπτωσης. Στοματολογία 62: 31-34 (2005)

8. Ruggierο S., Mehrotra B., Rosenberg T., Engroff S.: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62: 527-534 (2004)

9. Marx R., Cillo J., Ulloa J.: Oral bisphosphonate-Induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65: 2397-2410 (2007)

10. Bamias A., Kastritis E., Bamia C., Moulopoulos .LA., Melakopoulos I., Bozas G., et al.: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23: 8580-8587 (2005)

11. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65: 369-376 (2007)

12. Marx R.E., Sawatari Y., Fortin M., Broumand V.: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63: 1567-1575 (2005)

13. Migliorati C.A., Schubert M.M., Peterson D.E., Seneda L.M.: Bisphosphonate associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104: 83-93 (2005)

14. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulos I., et al.: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haemaologica 91: 968-971 (2006)

15. Dimopoulos M.A., Kastritis E., Bamia C., Melakopoulos I., Gika D., Roussou M., Migkou M., Eleftherakis-Papaiakovou E., Christoulas D., Terpos E., Bamias A.: Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20: 117-120 (2009)